Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Jing Zhao"'
Publikováno v:
Thoracic Cancer, Vol 14, Iss 35, Pp 3465-3474 (2023)
Abstract Background The Z0011 and AMAROS trials found that axillary lymph node dissection (ALND) was no longer mandatory for early‐stage breast cancer patients who had one or two metastatic axillary lymph nodes (mALNs). The aim of our study was to
Externí odkaz:
https://doaj.org/article/668ed1d331cf4713a1b567435955817a
Autor:
Haoran Zhang, Dongming Zhang, Jia Liu, Yuequan Shi, Xiaoyan Liu, Minjiang Chen, Wei Zhong, Jing Zhao, Yan Xu, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 32, Pp 3191-3201 (2023)
Abstract Background DNA damage response (DDR) pathways are essential to sustain genomic stability and play a critical role in cancer development and progression. Here, we investigated the profile of DDR gene mutations in early‐stage non‐small cel
Externí odkaz:
https://doaj.org/article/6cfb0de24fa641809786fad085b8d0c5
Autor:
Xiaoyan Si, Xueqing Zheng, Xinlun Tian, Hanping Wang, Yan Xu, Jing Zhao, Minjiang Chen, Wei Zhong, Mengzhao Wang, Li Zhang, Xiaotong Zhang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 21, Pp 2038-2044 (2023)
Abstract Background The discovery of immune checkpoint inhibitors (ICIs) is a breakthrough in the field of cancer therapy. However, ICIs may cause immune‐related adverse reactions, including checkpoint inhibitor‐related pneumonitis (CIP). The aim
Externí odkaz:
https://doaj.org/article/ec91e25e49c948a4ab5d9abb42e1647e
Autor:
Yuan Xu, Dongjie Ma, Yingzhi Qin, Shanqing Li, Ji Li, Ying Jiang, Mengzhao Wang, Yan Xu, Jing Zhao, Minjiang Chen, Wuying Cheng, Ke Hu, Hongsheng Liu
Publikováno v:
Thoracic Cancer, Vol 14, Iss 17, Pp 1635-1639 (2023)
Abstract Background Neoadjuvant immunotherapy combined with chemotherapy has been used to treat locally advanced non–small cell lung cancer (NSCLC). Several systems have been developed for response evaluation. The aim of this study was to evaluate
Externí odkaz:
https://doaj.org/article/ee71e7a2283645ed97731217a3734a1a
Autor:
Jia Liu, Minjiang Chen, Xiaoxing Gao, Xiaoyan Liu, Jing Zhao, Ruili Pan, Wei Zhong, Yan Xu, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 8, Pp 773-778 (2023)
Abstract Introduction Immune checkpoint inhibitor (ICI)‐based treatment regimens have become the standard of care for first‐line treatment of metastatic epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) wild‐type non‐sm
Externí odkaz:
https://doaj.org/article/7044e1192cda46f4b3e23f43c590c731
Autor:
Qing Zhou, Xiangning Liu, Ji Li, Bing Tong, Yan Xu, Minjiang Chen, Xiaoyan Liu, Xiaoxing Gao, Yuequan Shi, Jing Zhao, Wei Zhong, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 5, Pp 470-478 (2023)
Abstract Introduction This study investigated whether programmed death‐ligand 1 (PD‐L1) expression of circulating tumor cells (CTCs) in peripheral blood can serve as a predictive biomarker for immunotherapy efficacy in patients with advanced non
Externí odkaz:
https://doaj.org/article/33ac306df8ef419f88997f9415254a1d
Autor:
Jing Zhao, Yang Wu, Yuan Yue, Minjiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiaoyan Si, Wei Zhong, Xiaotong Zhang, Li Zhang, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 5, Pp 497-505 (2023)
Abstract Background Immune checkpoint inhibitors (ICIs) have become one important therapeutic strategy for advanced non‐small‐cell lung cancer (NSCLC). It remains imperative to identify reliable and convenient biomarkers to predict both the effic
Externí odkaz:
https://doaj.org/article/56b3c9c16b634f28bb0a279bd5b01767
Autor:
Xiaoxing Gao, Ruili Pan, Minjiang Chen, Jing Zhao, Wei Zhong, Hanping Wang, Xiaoyan Si, Xiaotong Zhang, Li Zhang, Yan Xu, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 7, Pp 1059-1066 (2022)
Abstract Background To investigate the prognostic value of magnetic resonance imaging (MRI) findings in the prognosis of patients with leptomeningeal metastasis from lung adenocarcinoma. Methods Patients with lung adenocarcinoma complicated with cyto
Externí odkaz:
https://doaj.org/article/f72a52fb918d4b98ac319cee30f7c275
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 353-360 (2022)
Abstract Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein involved in the metabolism of low‐density lipoprotein cholesterol. However, the role of plasma PCSK9 in predicting the efficacy of ICIs in advanced non
Externí odkaz:
https://doaj.org/article/81596293e4ea4521be8918086166d5e2
Autor:
Yuequan Shi, Jian Fang, Chengzhi Zhou, Anwen Liu, Yan Wang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Yu Yao, Hong Sun, Hui Guo, Cuiying Zhang, Xia Song, Junling Li, Bei Xu, Zhiqiang Han, Meijun Song, Tingyu Tang, Peifeng Chen, Hongmin Lu, Yongjie Shui, Guangyuan Lou, Dongming Zhang, Jia Liu, Xiaoyan Liu, Xiangning Liu, Xiaoxing Gao, Qing Zhou, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 412-422 (2022)
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly understood, especially in a real‐world setting. Methods A multicenter observation
Externí odkaz:
https://doaj.org/article/c5bf6538bfd04a4cb230f7fdea6625ff